托法替布治疗类风湿关节炎的缓解率:不同缓解标准的比较
该事后分析汇总5项III期随机对照研究共3306例类风湿关节炎患者,评估托法替布5 mg每日两次或10 mg每日两次(单药或联合传统合成改善病情抗风湿药)在不同缓解标准下的缓解率。结果显示各标准缓解率差异明显,DAS28-4(CRP)下缓解率最高,急性期反应物是否纳入标准是缓解率差异的重要来源。
要点
- 托法替布各剂量组缓解率均高于安慰剂,但幅度随缓解标准不同而变化。
- 第3个月托法替布5 mg每日两次时,DAS28-4(CRP)缓解率为18-22%,高于其他标准。
- 缓解标准中是否含急性期反应物及其类型显著影响各组缓解率。
核心结论
- 托法替布5 mg每日两次和10 mg每日两次较安慰剂有效,但采用DAS28-4(CRP)时缓解率明显更高,急性期反应物的有无与类型是缓解率的重要影响因素。
研究设计与样本
- 事后分析5项III期随机对照研究,共分析3306例患者:托法替布5 mg每日两次1213例、10 mg每日两次1212例、安慰剂679例、阿达木单抗40 mg每2周202例。
- 托法替布单药或联合甲氨蝶呤或其他传统合成改善病情抗风湿药给药;其中1项研究包含阿达木单抗40 mg每2周。
- 除III期研究主要疗效指标DAS28-4(ESR)外,事后采用DAS28-4(CRP)、CDAI、SDAI和Boolean法评估疾病活动度。
主要发现
- 缓解率随所用标准而变化,活性治疗组中DAS28-4(CRP)的缓解率高于其他评分。
- 第3个月托法替布5 mg每日两次的缓解率:DAS28-4(CRP)为18-22%,DAS28-4(ESR)为5-10%,SDAI为4-7%,CDAI为5-6%,Boolean法为2-7%。
- 安慰剂组缓解率为0%至7%,DAS28-4(ESR)与DAS28-4(CRP)之间差异较小。
关键数值与推荐
- DAS28-4(CRP)下托法替布5 mg每日两次第3个月缓解率为18-22%。
- DAS28-4(ESR)下托法替布5 mg每日两次第3个月缓解率为5-10%。
- SDAI下为4-7%,CDAI下为5-6%,Boolean法下为2-7%(均为托法替布5 mg每日两次第3个月)。
- 安慰剂组各标准缓解率为0%至7%。
临床怎么用
- 临床解读托法替布疗效数据时需注意所用缓解标准,含CRP的DAS28-4(CRP)所得缓解率明显高于ESR版本。
- 比较不同研究或不同药物的缓解率时应确认缓解标准及急性期反应物类型一致。
局限性
- 为事后分析,各缓解标准的评估并非III期研究预设的主要分析。
- 原文摘要未报告各标准间比较的统计学检验结果与置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tofacitinib is an oral JAK inhibitor that is used for the treatment of rheumatoid arthritis (RA). In previous clinical trials of tofacitinib, a Disease Activity Score in 28 joints (DAS28)-based analysis was used to assess outcomes. In this study, remission rates according to various remission criteria were evaluated across 5 phase III randomized controlled studies. METHODS: In all 5 studies, tofacitinib was administered at a dosage of 5 mg twice daily or 10 mg twice daily, either as monotherapy or with background methotrexate or other conventional synthetic disease-modifying antirheumatic drugs. One of the studies included adalimumab 40 mg once every 2 weeks. In addition to the 4-variable DAS28 using the erythrocyte sedimentation rate (DAS28-4[ESR]), a primary efficacy variable used in the phase III studies, disease activity was assessed post hoc by the 4-variable DAS28 using the C-reactive protein level (DAS28-4[CRP]), the Clinical Disease Activity Index (CDAI), the Simplified Disease Activity Index (SDAI), and Boolean-based assessment. RESULTS: A total of 3,306 patients were analyzed (1,213 of these patients received tofacitinib 5 mg twice daily, 1,212 received tofacitinib 10 mg twice daily, 679 received placebo, and 202 received adalimumab 40 mg every 2 weeks). Remission rates varied according to the criteria used, with higher rates in the active-treatment groups for the DAS28-4(CRP) than for other scores. At month 3, remission rates with tofacitinib 5 mg twice daily were 18-22% using the DAS28-4(CRP), 5-10% using the DAS28-4(ESR), 4-7% using the SDAI, 5-6% using the CDAI, and 2-7% using the Boolean-based method. In contrast, the remission rates with placebo varied from 0% to 7%, with small differences between the DAS28-4(ESR) and the DAS28-4(CRP). CONCLUSION: Although tofacitinib at dosages of 5 mg twice daily and 10 mg twice daily was effective compared with placebo in achieving disease remission, regardless of the disease activity measure, remission rates were substantially higher when the DAS28-4(CRP) was used. The presence or absence and type of acute-phase reactants in remission criteria were significant contributors to remission rates across treatment groups. This finding has important consequences for trial design and clinical practice.
引用
- Smolen JS, Aletaha D, Gruben D, et al. Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. Arthritis Rheumatol. 2017. PMID: 27907269. doi:10.1002/art.39996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。